ARWR

Peers: ALNY IONS SLN WVE DYN CRSP ABUS SRPT MDGL NTLA

| Held by: IJH VTI VB XBI VBK XMMO VXF MDY IBB IJK

Index	-
Market Cap	8.46B
Enterprise Value	8.23B
Income	-319.95M
Sales	669.50M
Book/sh	3.30
Cash/sh	11.34
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	711
IPO	Dec 16, 1993

P/E	-
Forward P/E	-
PEG	-
P/S	12.63
P/B	18.15
P/C	5.28
P/FCF	-
EV/EBITDA	-
EV/Sales	12.29
Quick Ratio	5.90
Current Ratio	5.90
Debt/Eq	2.96
LT Debt/Eq	2.86
Option/Short	Yes / Yes

EPS (ttm)	-2.24
EPS next Y	-4.86
EPS next Q	-1.52
EPS this Y	-35135.10%
EPS next Y	-37.82%
EPS next 5Y	-
EPS past 3/5Y	80.60% 57.10%
Sales past 3/5Y	50.52% 56.63%
EPS Y/Y TTM	-80.39%
Sales Y/Y TTM	16.85%
EPS Q/Q	-7.51%
Sales Q/Q	171.02%
Earnings	Aug 04 AMC
EPS/Sales Surpr.	-6.52% 70.36%

Insider Own	5.87%
Insider Trans	-0.20%
Inst Own	82.85%
Inst Trans	-3.20%
ROA	-18.32%
ROE	-64.78%
ROIC	-17.81%
Gross Margin	96.15%
Oper. Margin	-33.82%
Profit Margin	-47.79%
SMA20	0.95%
SMA50	-12.86%
SMA200	-16.48%
Trades

Shs Outstand	141.13M
Shs Float	132.97M
Short Float	8.24%
Short Ratio	6.40
Short Interest	10.96M
52W High	95.49 -37.31%
52W Low	37.06 61.54%
Volatility	3.83% 3.85%
ATR (14)	2.40
RSI (14)	41.25
Beta	1.37
Rel Volume	0.30
Avg Volume	1.71M
Volume	439,364

Perf Week	1.42%
Perf Month	-3.98%
Perf Quarter	-31.12%
Perf Half Y	-20.10%
Perf YTD	-9.83%
Perf Year	51.14%
Perf 3Y	112.67%
Perf 5Y	-25.57%
Perf 10Y	971.91%
Recom	1.12
Target Price	107.92
Prev Close	59.57
Price	59.87
Change %	0.50%

Consensus

Strong Buy

Avg. Price Target

$107.92

Implied Upside

+80.3%

Analysts14incl. previous ratings

Rating Distribution11 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 15, 2026	Resumed	UUBS	Buy	$109	+82.1%
Sep 24, 2026	Resumed	GGoldman	Neutral	$74	+23.6%
Sep 08, 2026	Initiated	CCitigroup	Buy	$108	+80.4%
Jul 14, 2026	Initiated	SStifel	Buy	$98	+63.7%
May 01, 2026	Initiated	JJP Morgan	Overweight	$88	+47.0%
Apr 21, 2026	Upgrade	MMorgan Stanley	Equal-Weight → Overweight	$100	+67.0%
Jun 05, 2024	Initiated	GGoldman	Neutral	$31	-48.2%
Dec 04, 2023	Initiated	BBofA Securities	Buy	$29	-51.6%
Sep 19, 2023	Initiated	CCitigroup	Neutral	$33	-44.9%
Jul 21, 2023	Initiated	TTD Cowen	Outperform
May 12, 2023	Downgrade	SSVB Securities	Outperform → Market Perform	$40	-33.2%
Apr 26, 2023	Initiated	SSMBC Nikko	Outperform	$80	+33.6%
Apr 12, 2023	Upgrade	SSVB Securities	Market Perform → Outperform	$21 → $35	-41.5%
Mar 21, 2023	Initiated	BBernstein	Mkt Perform	$27	-54.9%
Sep 09, 2022	Initiated	MMorgan Stanley	Equal-Weight	$41	-31.5%
May 11, 2022	Upgrade	RRobert W. Baird	Neutral → Outperform	$71 → $60	+0.2%
Jan 19, 2022	Resumed	GGoldman	Buy	$90 → $85	+42.0%
Aug 06, 2021	Reiterated	CChardan Capital Markets	Buy	$97 → $94	+57.0%
Jun 04, 2021	Resumed	RRobert W. Baird	Neutral	$85	+42.0%
Feb 05, 2021	Reiterated	HH.C. Wainwright	Buy	$90 → $95	+58.7%

Nov-02-26 06:30AM	Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026 (Business Wire)
Oct-28-26 06:50AM	Arrowhead gains UK marketing authorisation for Redemplo (Pharmaceutical Technology)
Oct-27-26 11:36AM	Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO (Plozasiran) as a New Treatment Option to Reduce Triglycerides (Business Wire)
Oct-14-26 01:21PM	Arrowheads Alzheimers disease drug reduces tau in Phase I/IIa trial (Clinical Trials Arena)
11:36AM	Arrowheads Alzheimers Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial Heres What Investors Need To Know (Stocktwits)
08:37AM	Loading…
08:37AM	Arrowhead jumps as breakthrough Alzheimers drug clears brain barrier (Investing.com)
07:30AM	Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers (Business Wire)
Oct-11-26 10:17PM	Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates The Weeks Biotech Watchlist (Stocktwits)
Oct-07-26 07:30AM	Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia (Business Wire)
Sep-29-26 07:30AM	Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies (Business Wire)
Sep-24-26 08:36PM	RNAi drug specialist ADARx raises $446M IPO (BioPharma Dive)
07:20AM	ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near (Stocktwits)
Sep-23-26 01:45AM	These 'Moonshot' Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right. (Barrons.com) -6.82%
Sep-16-26 01:41PM	Not A Gangbusters Launch Arrowhead Predicts Slow Burn to $3B-$4B Peak For Redemplo, Highlights Massive Pipeline (Stocktwits) -6.91%
Sep-15-26 03:03PM	ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data Is This A Sell The News Move? (Stocktwits) -12.40%
01:13PM	Loading…
01:13PM	FDA clears first generic radioligand drug; Sionna turns to layoffs (BioPharma Dive)
07:30AM	Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia (Business Wire)
Sep-04-26 12:13PM	This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging. (Barrons.com)
Sep-03-26 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences (Business Wire)
Aug-30-26 11:30AM	Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia (Business Wire)
Aug-24-26 07:30AM	Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress (Business Wire)
Aug-17-26 09:33AM	People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO (plozasiran) as a New Treatment Option to Reduce Triglycerides (Business Wire)
Aug-07-26 06:02AM	Significant demand for Revolution drug; Intellia pinpoints liver toxicity culprit (BioPharma Dive)
Aug-05-26 01:05AM	Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ... (GuruFocus.com)
Aug-04-26 04:17PM	Arrowhead Research: Fiscal Q3 Earnings Snapshot (Associated Press)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results (Business Wire)
Aug-03-26 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-27-26 07:30AM	Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia (Business Wire)
Jul-23-26 11:00AM	Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company? (Trefis)
Jul-22-26 06:44PM	ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data (Stocktwits) +19.03%
05:27PM	Loading…
05:27PM	Arrowhead Shares Soar on Strong Triglyceride Drug Data (The Wall Street Journal)
09:22AM	Why Arrowhead Shot Sky-High, While Its Chief Rival, Ionis, Toppled (Investor's Business Daily)
09:08AM	ARWR Stock On Track To Hit Over 5-Year Highs Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval (Stocktwits)
08:23AM	Arrowhead Pharmaceuticals shares surge after positive Phase 3 results for plozasiran (NASDAQ:ARWR) (InvestorsHub)
08:01AM	Arrowhead hits best-case scenario with latest results for fat-lowering drug (BioPharma Dive)
07:30AM	Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia (Business Wire)
Jul-21-26 07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results (Business Wire)
Jul-14-26 11:23AM	Arrowhead gains EU authorisation for Redemplo in evolving FCS market (Clinical Trials Arena)
Jul-13-26 02:00AM	Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's? (Barrons.com)
Jul-10-26 07:35AM	The Long Climb Back For Ionis Stock (Trefis) -9.05%
Jun-24-26 07:54PM	IONS Stock Jumps 4% After-Hours Goldman Sachs Lifts Price Target On Tryngolza Approval (Stocktwits)
Jun-22-26 12:33PM	Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) (Business Wire)
Jun-18-26 07:30AM	Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars (Business Wire)
Jun-02-26 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events (Business Wire) -5.82%
May-27-26 07:00AM	Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 (Business Wire)
May-26-26 10:00AM	Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress (Business Wire)
May-12-26 08:30AM	Wall Street's Cardiac Bet: Where Diagnostics Meet the Money (PR Newswire)
May-07-26 04:49PM	Arrowhead Research: Fiscal Q2 Earnings Snapshot (Associated Press) -6.75%
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results (Business Wire)
May-06-26 06:29AM	Arrowhead and Madrigal sign global licence for MASH RNAi therapy (Pharmaceutical Technology) +5.62%
May-05-26 11:53AM	Madrigal outlays $1bn for Arrowheads siRNA MASH asset (Pharmaceutical Technology)
08:00AM	Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals (Business Wire)
May-04-26 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events (Business Wire)
May-01-26 07:30AM	Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS) (Business Wire)
Apr-24-26 10:45AM	Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings (Pharmaceutical Technology)
06:39AM	Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe (Business Wire)
Apr-21-26 10:04AM	This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains. (Barrons.com)
10:03AM	Intel upgraded, Reddit initiated: Wall Street's top analyst calls (The Fly)
Apr-20-26 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results (Business Wire)
Mar-28-26 10:30AM	Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo (Business Wire)
Mar-25-26 01:10PM	Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets (Barrons.com) +8.00%
07:03AM	Sarepta sees early success with RNAi drugs from Arrowhead (BioPharma Dive)
Mar-24-26 11:05AM	Anti-Aging Protein Research Takes a Step Forward with Cell Cloning (PR Newswire)
Mar-04-26 08:48PM	Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference (MarketBeat)
Feb-26-26 10:29AM	Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates (Zacks)
Feb-24-26 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events (Business Wire)
Feb-18-26 12:54AM	Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)'s Familial Chylomicronemia Syndrome Likely Limited (Insider Monkey)
Feb-13-26 01:45PM	CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens (Benzinga)
Feb-07-26 10:40AM	Arrowhead price target lowered to $78 from $81 at Morgan Stanley (TipRanks)
Feb-06-26 12:04AM	Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... (GuruFocus.com)
Feb-05-26 08:06PM	Arrowhead Pharmaceuticals Q1 Earnings Call Highlights (MarketBeat) -5.02%
04:54PM	Arrowhead Research: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results (Business Wire)
Feb-04-26 06:15PM	Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 (PR Newswire) -5.66%
Jan-29-26 01:31PM	Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration (PR Newswire) +5.40%
Jan-27-26 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia (Business Wire)
Jan-22-26 03:20AM	Piper Sandler Highlights Arrowhead Pharmaceuticals, Inc. (ARWR) Pipeline With Upcoming Phase III Hypertriglyceridemia Data (Insider Monkey)
Jan-20-26 04:30PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results (Business Wire)
Jan-19-26 05:18PM	Arrowhead Pharmaceuticals, Inc. (ARWR): A Bull Case Theory (Insider Monkey)
Jan-12-26 05:43PM	Arrowhead Pharmaceuticals Touts Rudemplo Launch, Obesity RNAi Data and $920M Cash at JPM Conference (MarketBeat)
Jan-11-26 01:09AM	Piper Sandler Maintains an Overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR) (Insider Monkey)
Jan-07-26 11:05PM	Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants (Business Wire) -7.23%
07:30AM	Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China (Business Wire)
Jan-06-26 06:14PM	Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock (Business Wire) +10.85%
04:29PM	Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss (Investor's Business Daily)
11:26AM	Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay. (Barrons.com)
07:30AM	Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition (Business Wire)
Jan-05-26 07:30AM	Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) (Business Wire) -5.77%
Dec-23-25 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events (Business Wire)
Dec-15-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.54%
Dec-12-25 08:00AM	Arrowhead price target raised to $80 from $52 at RBC Capital (TipRanks)
Dec-08-25 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies (Business Wire) +11.65%
Dec-02-25 07:30AM	Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia (Business Wire)
Dec-01-25 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences (Business Wire) +6.74%
Nov-27-25 06:51AM	Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval (Insider Monkey)
Nov-26-25 07:16PM	Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today (Motley Fool) +23.34% -8.68%
05:47AM	Novartis cuts hundreds of jobs; Novos dual-acting diabetes drug heading to Phase 3 (BioPharma Dive)
12:00AM	Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ... (GuruFocus.com)
Nov-25-25 04:00PM	Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results (Business Wire) +5.72%
01:08PM	Sarepta's Stock Rises on Positive Updates on DM1 Therapy (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OLUKOTUN ADEOYE Y	Director	Aug 18 '26	Sale	86.96	2,000	173,920	31,600	Aug 20 05:25 PM
PERRY MICHAEL S	Director	Aug 18 '26	Sale	87.30	11,600	1,012,680	111,459	Aug 20 05:22 PM
Adeoye Olukotun	Director	Aug 18 '26	Proposed Sale	86.94	2,000	173,876		Aug 18 05:31 PM
Michael Perry	Director	Aug 18 '26	Proposed Sale	87.26	11,600	1,012,172		Aug 18 05:24 PM
Lu Hongbo	Director	May 12 '26	Sale	76.88	2,970	228,334	52,012	May 14 07:05 PM
Hongbo Lu	Officer	May 12 '26	Proposed Sale	76.87	2,970	228,299		May 12 04:35 PM
Apel Daniel Joseph	Chief Financial Officer	Apr 22 '26	Sale	71.35	13,095	934,285	162,905	Apr 24 06:44 PM
Hamilton James C	Chief Medical Officer	Apr 23 '26	Sale	75.00	10,000	750,000	226,958	Apr 24 06:38 PM
James Hamilton	Officer	Apr 23 '26	Proposed Sale	75.00	10,000	749,998		Apr 23 04:44 PM
Daniel Apel	Officer	Apr 22 '26	Proposed Sale	71.34	13,095	934,206		Apr 22 05:16 PM
Hamilton James C	Chief Medical Officer	Mar 05 '26	Sale	64.19	10,000	641,900	236,958	Mar 09 07:00 PM
James Hamilton	Officer	Mar 05 '26	Proposed Sale	64.19	10,000	641,870		Mar 05 04:49 PM
O'Brien Patrick	COO	Jan 05 '26	Sale	63.11	49,493	3,123,349	474,908	Jan 05 09:50 PM
Hamilton James C	Chief Medical Officer	Jan 05 '26	Sale	63.11	40,164	2,534,661	171,958	Jan 05 09:41 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 02 '26	Sale	66.10	13,187	871,703	3,792,739	Jan 05 09:39 PM
James Hamilton	Officer	Jan 05 '26	Proposed Sale	63.09	39,728	2,506,627		Jan 05 04:59 PM
Patrick O'Brien	Officer	Jan 05 '26	Proposed Sale	63.10	49,493	3,123,172		Jan 05 04:58 PM
Christopher Anzalone	Officer	Jan 02 '26	Proposed Sale	66.10	13,187	871,668		Jan 02 04:04 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 29 '25	Option Exercise	6.15	51,726	318,115	3,857,652	Dec 30 05:46 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 29 '25	Sale	69.13	51,726	3,575,575	3,805,926	Dec 30 05:46 PM
Ferrari Mauro	Director	Dec 26 '25	Sale	70.00	7,530	527,100	69,053	Dec 30 05:46 PM
Christopher Anzalone	Officer	Dec 29 '25	Proposed Sale	69.13	51,726	3,575,575		Dec 29 04:23 PM
Mauro Ferrari	Director	Dec 26 '25	Proposed Sale	70.00	7,530	527,070		Dec 29 04:03 PM
Waddill William D.	Director	Dec 19 '25	Sale	67.65	8,367	566,038	56,563	Dec 23 06:01 PM
Vakiener Victoria	Director	Dec 19 '25	Sale	67.68	10,040	679,491	35,723	Dec 23 06:01 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 19 '25	Sale	67.66	13,445	909,683	3,818,512	Dec 23 06:01 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 22 '25	Sale	68.44	12,586	861,340	3,805,926	Dec 23 06:01 PM
OLUKOTUN ADEOYE Y	Director	Dec 19 '25	Sale	67.66	10,000	676,623	33,600	Dec 23 06:01 PM
Christopher Anzalone	Officer	Dec 22 '25	Proposed Sale	68.43	12,586	861,319		Dec 22 04:00 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 17 '25	Sale	64.04	85,000	5,443,462	3,831,957	Dec 19 06:56 PM
Christopher Anzalone	Officer	Dec 19 '25	Proposed Sale	67.66	13,445	909,632		Dec 19 04:08 PM
William Waddill	Director	Dec 19 '25	Proposed Sale	67.65	8,367	566,001		Dec 19 04:07 PM
Adeoye Olukotun	Director	Dec 19 '25	Proposed Sale	67.66	10,000	676,589		Dec 19 04:07 PM
Victoria Vakiener	Director	Dec 19 '25	Proposed Sale	67.68	10,040	679,464		Dec 19 04:06 PM
Christopher Anzalone	Officer	Dec 17 '25	Proposed Sale	64.04	85,000	5,443,253		Dec 17 05:11 PM
Christopher Anzalone	Officer	Dec 16 '25	Proposed Sale	62.58	54,298	3,398,142		Dec 16 04:47 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 15 '25	Sale	68.85	130,000	8,950,615	3,971,255	Dec 16 01:14 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 16 '25	Sale	62.58	54,298	3,398,187	3,916,957	Dec 16 01:14 PM
Christopher Anzalone	Officer	Dec 15 '25	Proposed Sale	68.85	130,000	8,950,580		Dec 15 04:50 PM
PERRY MICHAEL S	Director	Dec 05 '25	Sale	61.03	16,250	991,738	115,240	Dec 09 06:04 PM
Michael Perry	Director	Dec 05 '25	Proposed Sale	60.99	16,250	991,129		Dec 05 04:00 PM
Ferrari Mauro	Director	Nov 28 '25	Sale	56.39	8,750	493,412	68,764	Dec 01 06:10 PM
Mauro Ferrari	Director	Nov 28 '25	Proposed Sale	56.35	8,750	493,062		Nov 28 01:19 PM

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

ChairmanDr. Christopher R. Anzalone Ph.D.

Chief Financial OfficerMr. Daniel J. Apel

PharmDMr. Patrick O'Brien J.D.

MBADr. James C. Hamilton M.D.

Founder and Founder & Director of Insert Therapeutics Inc & CalandoDr. Mark M. Davis Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Arrowhead Pharmaceuticals Inc

Upgrade your Finviz experience